Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Diagnosis

The novel PSMA ligand DKFZ-617 in the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumor lesions

Ali Afshar-Oromieh, Clemens Kratochwil, Martina Benesova, Matthias Eder, Klaus Kopka, Oliver Neels, Frederik Giesel and Uwe Haberkorn
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 398;
Ali Afshar-Oromieh
1Nuclear Medicine, University Hospital of Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Kratochwil
1Nuclear Medicine, University Hospital of Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Benesova
2Radiochemistry, German Cancer research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Eder
2Radiochemistry, German Cancer research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Kopka
2Radiochemistry, German Cancer research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Neels
2Radiochemistry, German Cancer research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Giesel
1Nuclear Medicine, University Hospital of Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
1Nuclear Medicine, University Hospital of Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 56 no. supplement 3 398

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 15, 2015.

Copyright & Usage 

Author Information

  1. Ali Afshar-Oromieh1,
  2. Clemens Kratochwil1,
  3. Martina Benesova2,
  4. Matthias Eder2,
  5. Klaus Kopka2,
  6. Oliver Neels2,
  7. Frederik Giesel1 and
  8. Uwe Haberkorn1
  1. 1Nuclear Medicine, University Hospital of Heidelberg, Heidelberg, Germany
  2. 2Radiochemistry, German Cancer research Center, Heidelberg, Germany

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2015 to April 2025

AbstractFullPdf
May 20152600
Jun 20157900
Jul 20154000
Aug 20154400
Sep 20151900
Oct 20151800
Nov 20152600
Dec 20151500
Jan 20161500
Feb 20162000
Mar 20161200
Apr 2016600
May 2016800
Jun 20161300
Jul 2016600
Aug 2016400
Sep 2016900
Oct 2016600
Nov 2016600
Dec 2016600
Jan 20171800
Feb 20171600
Mar 20171500
Apr 2017600
May 2017600
Jun 2017800
Jul 2017800
Aug 2017400
Sep 2017800
Oct 2017900
Nov 2017800
Dec 2017200
Jan 20181100
Feb 2018500
Mar 2018700
Apr 2018400
May 2018400
Jul 2018100
Aug 2018100
Sep 2018300
Nov 2018100
Dec 2018400
Feb 2019100
Mar 2019900
Apr 20194800
May 2019100
Jul 2019100
Sep 2019100
Nov 2019200
Feb 2020600
Mar 20201300
Apr 20201100
May 2020300
Jun 2020300
Jul 2020800
Aug 20201300
Sep 20202300
Oct 2020600
Nov 20201000
Dec 2020400
Jan 2021300
Feb 2021600
Mar 20211000
Apr 2021900
May 20211700
Jun 20211700
Jul 20215200
Aug 20218200
Sep 2021900
Oct 20215400
Nov 20213200
Dec 20211900
Jan 20223600
Feb 20221600
Mar 20221200
Apr 20222300
May 20221400
Jun 2022400
Jul 2022100
Aug 2022200
Sep 2022500
Oct 2022200
Nov 2022200
Dec 2022400
Jan 2023800
Feb 2023700
Mar 2023800
Apr 2023300
May 2023400
Jun 2023300
Jul 2023200
Aug 2023200
Sep 2023200
Oct 2023500
Nov 2023400
Dec 2023500
Jan 2024600
Feb 2024300
Mar 2024300
Apr 2024400
May 20241000
Jun 2024400
Jul 2024200
Aug 20241000
Sep 2024600
Oct 2024300
Nov 2024900
Jan 2025400
Feb 2025500
Mar 2025300
Apr 2025800
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The novel PSMA ligand DKFZ-617 in the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumor lesions
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The novel PSMA ligand DKFZ-617 in the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumor lesions
Ali Afshar-Oromieh, Clemens Kratochwil, Martina Benesova, Matthias Eder, Klaus Kopka, Oliver Neels, Frederik Giesel, Uwe Haberkorn
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 398;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The novel PSMA ligand DKFZ-617 in the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumor lesions
Ali Afshar-Oromieh, Clemens Kratochwil, Martina Benesova, Matthias Eder, Klaus Kopka, Oliver Neels, Frederik Giesel, Uwe Haberkorn
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 398;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Diagnosis

  • Additional value of PSMA-PET/CT in biochemical recurrence during follow-up of patients with prostate cancer.
  • Thymic epithelial tumors: Can FDG PET help in predicting histologic type and stage?
  • Interim FDG-PET/CT Interpreted with Qualitative Visual Trichotomous Assessment Criteria Predict Treatment Failure in Diffuse Large B-cell Lymphoma Treated with R-CHOP
Show more Oncology: Clinical Diagnosis

Prostate/GU I

  • Role of Ga-68 PSMA PET/CT in Theranostics of Metastasized Prostate Cancer
  • First-in-man analysis of [18F]DCFPyL, a second generation, 18F-labeled PSMA-targeted radiotracer, in patients with metastatic prostate cancer
  • 68Ga-PSMA dynamic PET/CT imaging of prostate cancer: Tracer distribution patterns and pharmacokinetics
Show more Prostate/GU I

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire